Axon Enterprise, Inc. — Q2 2023 Form 10-Q Summary
Business context and reporting period
Axon provides law-enforcement technology, including TASER devices, body-worn and in-car cameras, digital evidence management, cloud software, productivity tools, and real-time operations solutions. The filing covers the three and six months ended June 30, 2023, compared with the corresponding 2022 periods.
Key financial metrics
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Net sales | $374.6 million | $285.6 million | $717.6 million | $542.0 million |
| Net sales growth | 31.2% | — | 32.4% | — |
| Gross margin | $232.1 million; 62.0% | $174.0 million; 60.9% | $436.2 million; 60.8% | $329.7 million; 60.8% |
| Income from operations | $40.3 million; 10.8% | $21.4 million; 7.4% | $56.9 million; 7.9% | $38.6 million; 7.1% |
| Net income | $12.4 million | $51.0 million | $57.6 million | $105.8 million |
| Diluted EPS | $0.16 | $0.71 | $0.77 | $1.46 |
| Cash flow from operations | Not separately provided | Not separately provided | $(13.7) million | $63.3 million |
- Services revenue increased to $141.1 million in Q2, or 37.7% of sales, from $85.6 million, or 30.0%, in the prior-year quarter. Software and Sensors revenue rose 46.8% to $220.2 million, while TASER revenue increased 13.9% to $154.4 million.
- Q2 gross margin benefited from a higher mix of software revenue. TASER gross margin declined to 60.5% from 64.3%, primarily due to TASER 10 launch costs and manufacturing overhead. Software and Sensors gross margin increased to 63.0% from 57.9%.
- Operating expenses increased 25.8% in Q2 to $191.9 million, including higher compensation, commissions, research and development, and stock-based compensation.
- Net income was affected by a $71.9 million net unrealized impairment loss on a strategic investment and related warrants, partly offset by a $10.0 million unrealized gain on Cellebrite securities. The prior-year quarter included substantial net unrealized investment gains.
- At June 30, 2023, cash and cash equivalents were $474.2 million. Cash, cash equivalents, and investments totaled approximately $1.08 billion according to management’s discussion.
- The company had $690.0 million principal amount of 0.50% convertible senior notes due 2027, carried at $675.5 million net of issuance costs. No revolving credit borrowings were outstanding.
- The $200.0 million revolving credit facility had $192.6 million of availability after $7.4 million of letters of credit. The reported net leverage ratio was 0.45 to 1.00 versus a maximum of 3.50 to 1.00.
Material changes versus the prior comparable period
- Revenue growth was driven by Axon Evidence and cloud services, Fleet systems, TASER 10 devices, and increased users and devices on the Axon network.
- Q2 operating income increased $18.8 million, while the operating margin improved to 10.8% from 7.4%.
- Net income and EPS declined sharply because the prior-year period benefited from investment gains, while Q2 2023 included a significant strategic-investment impairment.
- Six-month operating cash flow declined to negative $13.7 million from positive $63.3 million. Working-capital uses included a $102.2 million increase in accounts receivable and contract assets, a $43.6 million inventory increase, and a $49.3 million increase in prepaid expenses and other assets.
- Financing activities generated $52.3 million in the first half, primarily from $94.8 million of net ATM offering proceeds and $54.5 million from stock-option exercises, partly offset by $97.1 million of employee tax payments related to net-settled stock awards.
- Deferred revenue increased to $677.7 million from $608.0 million at December 31, 2022. Remaining performance obligations were approximately $5.2 billion; management expects to recognize 15%–25% during the next twelve months, subject to deployment, appropriation, and cancellation risks.
Guidance, outlook, commentary, and unusual items
- The filing does not provide formal full-year revenue or earnings guidance. Management states that available funding, including cash, investments, operating resources, and the revolver, is expected to satisfy anticipated requirements for at least the next twelve months.
- Management highlighted continued demand for Axon Evidence, Fleet 3, TASER 10, and the broader integrated hardware-and-cloud platform. Axon Body 4 began shipping near the end of Q2.
- Management expects TASER 10 launch-related manufacturing overhead and scale inefficiencies to affect margins, while product mix and software growth support consolidated margins.
- Stock-based compensation expense was $66.2 million in the first half, including the vesting of significant XSPP and CEO performance awards. Additional unrecognized compensation costs remained for RSUs and PSUs.
- The company identified a material weakness in internal control over financial reporting involving software and services revenue and deferred revenue following an ERP and quote-to-cash systems migration. Remediation was underway but had not been completed or tested; disclosure controls were therefore considered ineffective as of June 30, 2023.
- Axon faces three product-liability lawsuits involving alleged wrongful death or personal injury. Management does not currently expect the proceedings to materially affect financial position, results, or cash flows, but litigation outcomes remain uncertain.
- The FTC administrative action concerning the Vievu acquisition was withdrawn from adjudication on June 20, 2023, to facilitate discussions. The matter remains unresolved.
- Key risks include government budget and appropriation constraints, contract cancellation rights, supply-chain limitations, TASER 10 regulatory requirements, cybersecurity and cloud-service interruptions, product liability, investment volatility, foreign exchange exposure, tax uncertainty, and potential dilution from convertible notes, warrants, and equity compensation.
Most important facts for investors to verify
- Whether the revenue-recognition and deferred-revenue material weakness is remediated and independently tested in subsequent filings.
- Conversion, settlement, and dilution implications of the $690.0 million convertible notes, related note hedge, and 3.0 million warrants with a $338.86 strike price.
- Cash conversion and working-capital trends, particularly receivables, contract assets, inventory, deferred commissions, and operating cash flow.
- Sustainability of demand and margins for TASER 10, Fleet, Axon Evidence, and professional services as product mix changes.
- Future fair-value changes or impairments involving the strategic investment portfolio and Cellebrite securities.
- Developments in the FTC matter, product-liability cases, grand-jury inquiry referenced in the risk factors, and other regulatory or intellectual-property proceedings.
- Government customer funding, renewal, appropriation, and cancellation trends supporting the approximately $5.2 billion of remaining performance obligations.